Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Arcturus Therapeutics and Janssen Pharmaceuticals have entered into a research collaboration and worldwide license agreement to discover and develop RNA medicines for defined indications.
Subscribe to our email newsletter
The deal, facilitated by J&J Innovation, will see the two firms jointly develop and commercialize RNA-based drug products to treat specified diseases using Arcturus’ UNA Oligomer chemistry and Lunar nanoparticle delivery platform.
Arcturus Therapeutics president and CEO Joseph Payne said: "We are pleased to be collaborating with a top tier pharmaceutical company like Janssen.
"Arcturus is thrilled to be working together with Janssen to identify an RNA treatment for one of the pharmaceutical industry’s most challenging disease targets."
Under the deal, Arcturus will receive an upfront payment, R&D support, and pre-clinical, development and sales milestone payments, as well as royalty payments on any future licensed product sales.
Janssen will be responsible for development costs and all commercialization costs associated with the program.
The deal brings together Arcturus’ expertise and intellectual property in the field of RNA medicines along with Janssen’s clinical development, regulatory, and marketing proficiency.
Arcturus’ RNA therapeutics platform can be applied to all types of RNA medicines such as small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics.